In a mouse ovarian cancer model, the peptide sv6D significantly inhibited the formation of ascites when combined with the chemotherapeutic agent paclitaxel or an immunotherapeutic antibody against the receptor PD-1 (106).Combining EP-100 with PARP inhibitor (olaparib) significantly increased the number of nuclear foci of phosphorylated histone H2AX, leading to increased DNA damage in ovarian cancer cells (111). This evidence concerns the gene H2AX and ovarian carcinoma.